143 related articles for article (PubMed ID: 21888984)
1. hERG potency estimates based upon dose solution analysis: What have we learned?
Qu Y; Schnier P; Zanon R; Vargas HM
J Pharmacol Toxicol Methods; 2011; 64(3):251-7. PubMed ID: 21888984
[TBL] [Abstract][Full Text] [Related]
2. Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and NaV1.5 blockade.
Donovan BT; Bakshi T; Galbraith SE; Nixon CJ; Payne LA; Martens SF
J Pharmacol Toxicol Methods; 2011; 64(3):269-76. PubMed ID: 21996251
[TBL] [Abstract][Full Text] [Related]
3. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells.
Du X; Lu D; Daharsh ED; Yao A; Dewoody R; Yao JA
J Pharmacol Toxicol Methods; 2006; 54(2):164-72. PubMed ID: 16782359
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
6. Halide ion effects on human Ether-à-go-go related gene potassium channel properties.
Zeng H; Balasubramanian B; Penniman JR; Kinose F; Salata JJ; Lagrutta A
Assay Drug Dev Technol; 2013; 11(9-10):544-50. PubMed ID: 24147984
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
Sorota S; Zhang XS; Margulis M; Tucker K; Priestley T
Assay Drug Dev Technol; 2005 Feb; 3(1):47-57. PubMed ID: 15798395
[TBL] [Abstract][Full Text] [Related]
9. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
11. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
12. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
13. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
14. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature.
Yao JA; Du X; Lu D; Baker RL; Daharsh E; Atterson P
J Pharmacol Toxicol Methods; 2005; 52(1):146-53. PubMed ID: 15936218
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
16. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.
Kirsch GE; Trepakova ES; Brimecombe JC; Sidach SS; Erickson HD; Kochan MC; Shyjka LM; Lacerda AE; Brown AM
J Pharmacol Toxicol Methods; 2004; 50(2):93-101. PubMed ID: 15385083
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
Zhao J; Lian Y; Lu C; Jing L; Yuan H; Peng S
J Ethnopharmacol; 2012 Jun; 141(2):685-91. PubMed ID: 21920426
[TBL] [Abstract][Full Text] [Related]
18. Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
Lee SH; Sung MJ; Hahn SJ; Kim J; Min G; Jo SH; Choe H; Choi BH
Arch Pharm Res; 2012 Sep; 35(9):1655-64. PubMed ID: 23054723
[TBL] [Abstract][Full Text] [Related]
19. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential.
Himmel HM
J Pharmacol Toxicol Methods; 2007; 56(2):145-58. PubMed ID: 17590357
[TBL] [Abstract][Full Text] [Related]
20. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
